Asthma Clinical Trial
Official title:
Environmental Polymorphisms Registry Health and Exposures Survey
The Environmental Polymorphisms Registry (EPR) Health and Exposure Survey is designed to
gather health, family history of disease, environmental exposures and lifestyle data on adult
EPR subjects. The EPR is a registry established to collect and store DNA samples from 20,000
volunteers from North Carolina and to serve as a resource to scientist investigating
genotype-driven translational research of chronic conditions. Under this new protocol, we
will administer a health and exposures survey to all EPR subjects. The information collected
in the survey will be used to better characterize the EPR population thus making it more
useful to NIEHS researchers. The survey contains approximately 200 questions. Data from the
survey will help researchers develop hypotheses, design follow-up studies, and select
appropriate subjects.
The survey will be administered to EPR subjects using a modified version of the Dillman Total
Design Method (TDM) for surveys. This method requires following specific time-dependent steps
for survey administration that incorporate both self- and phone administration and other
types of phone and mail contact. The goal of TDM is to maximize subject response rates.
The Environmental Polymorphisms Registry (EPR) Health and Exposure Survey is designed to
collect health, family history of disease, environmental exposures and lifestyle data on EPR
participants. The EPR was established to collect and store DNA specimens from 20,000
participants and to serve as a resource for scientists investigating genotype-driven
translational research of chronic health conditions. Under this protocol, we will administer
the approximately 200 question Health and Exposure Survey to EPR participants. The
information will be used to better characterize the EPR population, thus making it more
useful in answering research questions related to gene-environment interactions. Data from
the survey will help researchers to advance clinical research by developing new ways of
preventing, diagnosing, and treating common diseases such as cardiovascular disease, asthma,
and diabetes.
During Phases I and II, the survey was administered to EPR participants using a modified
version of the Dillman Total Design Method (TDM) for surveys. This method requires following
specific steps for survey administration that incorporate web-based, paper and phone
administration. The rationale for using the TDM is to maximize participant response rates.
During Phase III, the survey may be distributed to new EPR participants (e.g., those who were
not enrolled in the EPR at the time of the Phase I and II survey administrations) for
self-administration at the time of enrollment.
Investigators may select and contact participants for follow-up studies based upon health,
exposure, or disease status information; this includes responses to the EPR Health and
Exposure Survey. Participation in follow-up studies is completely voluntary. Participants can
decide at the time they are contacted if they would like to enroll in the follow-up study.
Their decision whether or not to participate in a follow-up study will not affect their
participation in the EPR.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|